Spyre Therapeutics, Inc. (SYRE) stock
SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
$96.56−2.40 (-2.43%)
Close on Oct 30, 2026Market cap $8.51BP/E –Yield –
Earnings
Spyre Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 3, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
–
EPS, Q2 FY2026
-$0.36
-$0.49 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Spyre Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 3, 2026Expected | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 4, 2026after the close | – | – | -$0.36 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 5, 2026before the open | – | – | -$0.74 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 19, 2026after the close | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 4, 2025after the close | – | – | -$0.15 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025after the close | – | – | -$0.49 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025after the close | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025after the close | – | – | -$0.81 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024after the close | – | – | -$1.36 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 7, 2024after the close | – | – | -$0.86 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024after the close | – | – | -$1.20 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 29, 2024after the close | – | – | -$4.05 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023after the close | – | – | -$9.34 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 11, 2023before the open | $700.00K | +16.7% | -$2.27 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 11, 2023before the open | $200.00K | -85.7% | -$0.20 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 2, 2023before the open | $200.00K | -94.4% | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022before the open | $174.00K | -87.6% | -$0.19 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022before the open | $600.00K | – | -$0.27 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022before the open | $1.40M | – | -$0.37 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 8, 2022before the open | $3.60M | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021before the open | $1.40M | – | -$0.31 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 10, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 18, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020before the open | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 10, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Spyre Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Spyre Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Spyre Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Results
- Update
- Results
- Update
- Update
- Results
- Update
- Update
- Results
- Results
- Results
- Update
- Update